Semaglutide
PLASTIC
Novo Nordisk · Phase 3 · Not yet recruiting · Enrollment 120
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Pubertal Adolescent - Continuous Treatment | n/r | n/r | n/r | n/r |
| Pubertal Adolescent - Early Treatment Cessation | n/r | n/r | n/r | n/r |
| Post-Pubertal Adolescent - Continuous Treatment | n/r | n/r | n/r | n/r |
| Post-Pubertal Adolescent - Early Treatment Cessation | n/r | n/r | n/r | n/r |
| Adult - Continuous Treatment | n/r | n/r | n/r | n/r |
| Adult - Early Treatment Cessation | n/r | n/r | n/r | n/r |
Not shown
- Pubertal Adolescent - Continuous Treatment: endpoint not reported
- Pubertal Adolescent - Early Treatment Cessation: endpoint not reported
- Post-Pubertal Adolescent - Continuous Treatment: endpoint not reported
- Post-Pubertal Adolescent - Early Treatment Cessation: endpoint not reported
- Adult - Continuous Treatment: endpoint not reported
- Adult - Early Treatment Cessation: endpoint not reported